domingo, 16 de diciembre de 2018

Forbes "Power Women 2018": De 100 solo 2...


Solo 2 de 100 (Pharma) mujeres en el Ranking Forbes "Power Woman 2018"

#18 Emma Walmsley   49   U.K

• Walmsley became CEO of GlaxoSmithKline in April of 2017, making her the first (and only) woman to run a major pharmaceutical company.
• Since taking helm of the 300-year-old company, she led a global restructuring program aimed at saving more than $500 million a year by 2021.
• The savings will be invested in R&D spending and funding a pipeline of new products.
• In one of her biggest moves since becoming CEO, Walmsley led this year's $13 billion dollar purchase of Novartis's 36% stake in GSK Consumer Health.
• The deal will allow the drug giant to focus on its three core businesses: pharmaceuticals, vaccines and consumer healthcare.
• In July 2018, she announced a $300 million deal with 23andMe, a San Francisco genetics startup, to develop new medicines.

Ver también: 
Big Pharma’s Latest Breakthrough: Choosing Its First Female Glaxo CEO Emma Walmsley

#60 Kiran Mazumdar-Shaw    65    India

· Mazumdar-Shaw, India's richest self-made woman, founded India's largest biopharmaceutical firm in 1978.
· The firm has successfully forayed into the lucrative US biosimilars market, catching the attention of investors and creating a surge in market cap.
· Biocon became the first company to gain approval from the US FDA for two different biosimilars of drugs used in certain cancer treatments.
· She's invested in research infrastructure and scientific talent with the aim of building a deep R&D-based biotech firm, not a copycat generics maker.
· Her philanthropic initiative, The Mazumdar Shaw Medical Centre, aims to create a sustainable, affordable cancer care model.

No hay comentarios: